Literature DB >> 32057310

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome.

Carmen Martínez Cué1, Mara Dierssen2.   

Abstract

Early intervention and environmental optimization have been central to management of Down syndrome (DS) and much of current treatment is still focused in strategies that involve early education plans. This approach has provided significant improvements for Down syndrome but it is not providing a full success. The discovery of an increasing number of genes and molecular pathways linked to intellectual disability and involving a range of synaptic and plasticity-related mechanisms has open new treatment opportunities that focus on targeted treatments boosting neural plasticity. We here discuss some of these approaches, focusing on the effects of environmental enrichment and on the discovery of pharmacological therapies showing beneficial effects even in some clinical trials in adult individuals with Down syndrome. Targeting plasticity impairments in DS is thus a promising strategy to promote cellular mechanisms involved in learning and memory within key cognitive brain region and could lead to improved connectivity.
© 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EGCG; Environ-mimetic drugs; Environmental enrichments; Epigenetics; Neuronal plasticity

Mesh:

Substances:

Year:  2019        PMID: 32057310     DOI: 10.1016/bs.pbr.2019.11.001

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  5 in total

Review 1.  Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome.

Authors:  Christophe Noll; Janany Kandiah; Gautier Moroy; Yuchen Gu; Julien Dairou; Nathalie Janel
Journal:  Nutrients       Date:  2022-05-12       Impact factor: 6.706

2.  Behavioral Phenotyping for Down Syndrome in Mice.

Authors:  Randall J Roper; Charles R Goodlett; María Martínez de Lagrán; Mara Dierssen
Journal:  Curr Protoc Mouse Biol       Date:  2020-09

3.  Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.

Authors:  Charles R Goodlett; Megan Stringer; Jonathan LaCombe; Roshni Patel; Joseph M Wallace; Randall J Roper
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

4.  Regulation of Neurogenesis in Mouse Brain by HMGB1.

Authors:  Xiang Zhao; Ari Rouhiainen; Zhilin Li; Su Guo; Heikki Rauvala
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

Review 5.  Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions.

Authors:  Mara Dierssen; Marta Fructuoso; María Martínez de Lagrán; Marzia Perluigi; Eugenio Barone
Journal:  Front Neurosci       Date:  2020-07-08       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.